DOCSLIB.ORG

Aberrant Dna Methylation in Human Non-Small Cell Lung Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aberrant Dna Methylation in Human Non-Small Cell Lung Cancer ABERRANT DNA METHYLATION IN HUMAN NON-SMALL CELL LUNG CANCER DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Romulo Martin Brena, B.A. ***** The Ohio State University 2007 Dissertation Committee: Approved by: Dr. Christoph Plass, Adviser Dr. Thomas J. Rosol ____________________________________ Dr. Michael C. Ostrowski Adviser Graduate Program in Molecular Genetics Dr. Gregory A. Otterson Dr. Laura J. Rush ABSTRACT Lung cancer is the leading cause of cancer-related death worldwide. Given its impact on human health, extensive research is being conducted in an effort to reduce the global lung cancer death toll. Specifically, much interest has been placed on the development of biomarkers and the discovery of novel prognostic factors. Over the past 2 decades it has become evident that the cancer genome is not only affected by genetic abnormalities, such as mutations, deletions and chromosomal rearrangements, but also by epigenetic changes which, together, contribute to the deregulation of transcription profiles. Epigenetic changes are defined as heritable lesions to the DNA affecting gene expression without altering the primary DNA sequence. These lesions typically involve a genomewide reduction in 5-methylcytosine, increased DNA methylation in gene promoter sequences and substitutions in histone tail modifications. Epigenetic changes have been shown to interact with one another, resulting in genomic instability, silencing of tumor suppressor genes, activation of oncogenes and derepression of transposable elements. As opposed to the irreversible nature of genetic lesions, epigenetic lesions can be reversed. Because of their reversibility, epigenetic alterations have become an attractive target for new therapies, which has resulted in the development of new anticancer compounds, several of which are currently in clinical trials. ii The field of epigenetics has expanded considerably since its inception. Integrative research approaches aimed at elucidating the contribution of genetic and epigenetic alterations to the tumorigenic process are being undertaken worldwide, generating promising results. In hopes of furthering the body of knowledge currently afforded by the epigenetics field, the work presented in this thesis is focus primarily on unraveling the role of DNA methylation in the diagnosis, etiology and potential treatment of lung cancer. Early detection would play a major role in reducing lung cancer-related death. Since standardized early detection methods for lung cancer are currently lacking, extensive efforts have been devoted in the lung cancer field to the identification of molecular markers which might be useful for disease detection or which might afford improvement in prognostic parameters. In recent months, several studies have reported important advances in these two areas. Lu and colleagues were able to identify a gene expression signature that helps predict survival of patients with stage I non-small cell lung cancer. Following a similar investigative approach, Chen and colleagues reported a 5 gene expression signature that correlates with clinical outcome in non-small cell lung cancer patients, regardless of stage. Other investigators, such as Guo et al and Raponi et al have focus primarily on specific lung cancer subtypes and have reported molecular classifiers that help refine the clinical prognosis of adenocarcinomas and squamous cell carcinomas, respectively. Other prominent investigators in the lung cancer field have focused their efforts on the discovery of markers which could be utilized for early detection. A landmark study on this line of research has recently been published by Shames and colleagues. These investigators reported a number of molecular markers that could help detect not only lung cancer, but also other types of common neoplasias, such as those of the breast and colon. The importance of this study resides in that it is iii one of the few research endeavors geared towards the discovery of pan-cancer markers. Furthermore, Shames and colleagues decided to focus on aberrant DNA methylation as a marker for neoplasias, an emerging investigative approach of great potential that still remains to be fully explored. Following this line of investigation, we hypothesize that epigenetic abnormalities, in particular aberrant DNA methylation, is involved in the etiology of lung cancer. Furthermore, we hypothesized that different non-small cell lung cancer subtypes can be distinguished by their aberrant DNA methylation profiles. We tested our hypotheses by analyzing human primary lung tumors via Restriction Landmark Genomic Scanning (RLGS) in an effort to identify not only novel DNA methylation targets, but also targets specific to lung cancer. In Chapter 1, we introduce DNA methylation as biological process intimately involved in the regulation of key cellular functions, from early development to adulthood. We continue to expand on how DNA methylation is involved in human cancer and particularly discuss the identification of key genes silenced by DNA methylation in lung cancer. We conclude the chapter by discussing how DNA methylation could be used as a biomarker and a prognostic marker in lung cancer. Chapter 2 provides a synopsis of the techniques currently available for the assessment of DNA methylation, coupled with a discussion on the suitability of each of these techniques for their application in disease diagnosis and classification. We put special emphasis on addressing the applicability of these techniques in clinical settings, in an effort to highlight the current disconnect between bench work achievements and their translation into novel approaches which could directly impact patient lives. Chapter 3 describes a novel technique, Bio-COBRA, for the quantitative analysis of DNA methylation. Specifically, we discuss how the determination of DNA methylation iv levels in a quantitative and reproducible manner could aid in increasing the efficacy of treatments involving DNA demethylating agents. In Chapter 4, we describe a genomewide DNA methylation scan of primary human lung adenocarcinomas and squamous cell carcinomas. Our scan revealed that these two lung cancer subtypes can in fact be distinguished based on their aberrant DNA methylation profiles. Also, we report the discovery a novel prognostic factor, oligodendrocyte transcription factor 1 (OLIG1), whose expression at the protein level was strongly correlated with survival in patients suffering from non-small cell lung cancer. Chapter 5 presents a survey of lung-specific DNA methylation events, as determined by comparing NotI RLGS profiles from human cancers derived from 12 different organs. Our survey showed that lung cancer is the neoplasia with the highest number of tumor-specific aberrant DNA methylation events. We performed extensive mRNA expression and DNA methylation analyses in an effort to provide a comprehensive report of the genes most frequently silenced by lung-specific DNA methylation. Finally, we conclude with Chapter 6, where we discuss the future steps that need to be taken in order to further the current understanding of how aberrant DNA methylation impacts the etiology of lung cancer. v Dedicated to my family and to all those whose constant support has helped me made a small contribution towards the advancement of science vi ACKNOWLEDGMENTS The past 6 years have been a memorable journey. This journey, like many others, seemed, at times, of uncertain destination. However, now that I find myself at the end of its road, I can clearly see the destination had always been there. Knowing this about the journey might enable me to impart some words of wisdom to future travelers, to let them know that although it may seem unattainable at times, they will also get to the journey’s end. Past travelers did impart those same words to me, but they did not resonate as loudly as they would today. Nevertheless, their intention to pass on their experience and encouragement was unmistakable, for which I will always be grateful. Many people have helped me get to the point where I can finally be writing these words. There are so many in fact that, I will certainly forget to mention some of them, for which I apologize in advance. First, I would like to thank Dr. Christoph Plass, whose incredible patience has made me realize that the best attribute of a great mentor is being able to make his students feel they are always welcome and that no question or concern is too trite for his attention. Dr. Thomas Rosol and Dr. Laura Rush have been instrumental in my learning to look at scientific problems not just from a molecular standpoint, but as a puzzle that affects an entire being, whether it be human or animal, and that the answer to solving the puzzle most likely entails thinking about that being as a whole. I would also like to thank Dr. Rush for her constant support and for saying the right words at the right time to help me stay on track. vii A very special thank you goes to Dr. Sandya Liyanarachchi, who not only played a central role in the statistical analysis of the data for almost all my research projects, but who also permanently took time out of her busy schedule to teach me about the theoretical background involved in her work. Dr. Liyanarachchi’s involvement in my graduate career has been fundamental in my training to be able to critically assess the validity of statistical analyses presented in biomedical research publications.
Load more

Recommended publications
  • DNA Methylation of GHSR, GNG4, HOXD9 and SALL3 Is a Common Epigenetic Alteration in Thymic Carcinoma
    INTERNATIONAL JOURNAL OF ONCOLOGY 56: 315-326, 2020 DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma REINA KISHIBUCHI1, KAZUYA KONDO1, SHIHO SOEJIMA1, MITSUHIRO TSUBOI2, KOICHIRO KAJIURA2, YUKIKIYO KAWAKAMI2, NAOYA KAWAKITA2, TORU SAWADA2, HIROAKI TOBA2, MITSUTERU YOSHIDA2, HIROMITSU TAKIZAWA2 and AKIRA TANGOKU2 1Department of Oncological Medical Services, Graduate School of Biomedical Sciences, Tokushima University, Tokushima 770-8509; 2Department of Thoracic, Endocrine Surgery and Oncology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima 770-8503, Japan Received August 17, 2019; Accepted October 25, 2019 DOI: 10.3892/ijo.2019.4915 Abstract. Thymic epithelial tumors comprise thymoma, promoter methylation of the 4 genes was not significantly thymic carcinoma and neuroendocrine tumors of the thymus. higher in advanced-stage tumors than in early-stage tumors in Recent studies have revealed that the incidence of somatic all thymic epithelial tumors. Among the 4 genes, relapse-free non‑synonymous mutations is significantly higher in thymic survival was significantly worse in tumors with a higher DNA carcinoma than in thymoma. However, limited information methylation than in those with a lower DNA methylation in all is currently available on epigenetic alterations in these types thymic epithelial tumors. Moreover, relapse-free survival was of cancer. In this study, we thus performed genome-wide significantly worse in thymomas with a higher DNA methyla- screening of aberrantly methylated CpG islands in thymoma tion of HOXD9 and SALL3 than in those with a lower DNA and thymic carcinoma using Illumina HumanMethylation450 methylation. On the whole, the findings of this study indicated K BeadChip. We identified 92 CpG islands significantly that the promoter methylation of cancer-related genes was hypermethylated in thymic carcinoma in relation to thymoma significantly higher in thymic carcinoma than in thymoma and and selected G protein subunit gamma 4 (GNG4), growth the thymus.
    [Show full text]
  • The 4D Nucleome Project
    The 4D nucleome project The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Dekker, Job et al. “The 4D Nucleome Project.” Nature 549, no. 7671 (September 2017): 219–226 © 2017 Macmillan Publishers Limited, part of Springer Nature As Published http://dx.doi.org/10.1038/NATURE23884 Publisher Nature Publishing Group Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/114838 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nature. Manuscript Author Author manuscript; Manuscript Author available in PMC 2017 September 27. Published in final edited form as: Nature. 2017 September 13; 549(7671): 219–226. doi:10.1038/nature23884. The 4D Nucleome Project Job Dekker1, Andrew S. Belmont2, Mitchell Guttman3, Victor O. Leshyk4, John T. Lis5, Stavros Lomvardas6, Leonid A. Mirny7, Clodagh C. O’Shea8, Peter J. Park9, Bing Ren10, Joan C. Ritland Politz11, Jay Shendure12, Sheng Zhong4, and the 4D Nucleome Network13 1Program in Systems Biology, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Howard Hughes Medical Institute, Worcester, MA 01605 2Department of Cell and Developmental Biology, University of Illinois, Urbana-Champaign, IL 61801 3Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125 4Department
    [Show full text]
  • The International Human Epigenome Consortium (IHEC): a Blueprint for Scientific Collaboration and Discovery
    The International Human Epigenome Consortium (IHEC): A Blueprint for Scientific Collaboration and Discovery Hendrik G. Stunnenberg1#, Martin Hirst2,3,# 1Department of Molecular Biology, Faculties of Science and Medicine, Radboud University, Nijmegen, The Netherlands 2Department of Microbiology and Immunology, Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada V6T 1Z4. 3Canada’s Michael Smith Genome Science Center, BC Cancer Agency, Vancouver, BC, Canada V5Z 4S6 #Corresponding authors [email protected] [email protected] Abstract The International Human Epigenome Consortium (IHEC) coordinates the generation of a catalogue of high-resolution reference epigenomes of major primary human cell types. The studies now presented (cell.com/XXXXXXX) highlight the coordinated achievements of IHEC teams to gather and interpret comprehensive epigenomic data sets to gain insights in the epigenetic control of cell states relevant for human health and disease. One of the great mysteries in developmental biology is how the same genome can be read by cellular machinery to generate the plethora of different cell types required for eukaryotic life. As appreciation grew for the central roles of transcriptional and epigenetic mechanisms in specification of cellular fates and functions, researchers around the world encouraged scientific funding agencies to develop an organized and standardized effort to exploit epigenomic assays to shed additional light on this process (Beck, Olek et al. 1999, Jones and Martienssen 2005, American Association for Cancer Research Human Epigenome Task and European Union 2008). In March 2009, leading scientists and international health research funding agency representatives were invited to a meeting in Bethesda (MD, USA) to gauge the level of interest in an international epigenomics project and to identify potential areas of focus.
    [Show full text]
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells
    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
    [Show full text]
  • Watsonjn2018.Pdf (1.780Mb)
    UNIVERSITY OF CENTRAL OKLAHOMA Edmond, Oklahoma Department of Biology Investigating Differential Gene Expression in vivo of Cardiac Birth Defects in an Avian Model of Maternal Phenylketonuria A THESIS SUBMITTED TO THE GRADUATE FACULTY In partial fulfillment of the requirements For the degree of MASTER OF SCIENCE IN BIOLOGY By Jamie N. Watson Edmond, OK June 5, 2018 J. Watson/Dr. Nikki Seagraves ii J. Watson/Dr. Nikki Seagraves Acknowledgements It is difficult to articulate the amount of gratitude I have for the support and encouragement I have received throughout my master’s thesis. Many people have added value and support to my life during this time. I am thankful for the education, experience, and friendships I have gained at the University of Central Oklahoma. First, I would like to thank Dr. Nikki Seagraves for her mentorship and friendship. I lucked out when I met her. I have enjoyed working on this project and I am very thankful for her support. I would like thank Thomas Crane for his support and patience throughout my master’s degree. I would like to thank Dr. Shannon Conley for her continued mentorship and support. I would like to thank Liz Bullen and Dr. Eric Howard for their training and help on this project. I would like to thank Kristy Meyer for her friendship and help throughout graduate school. I would like to thank my committee members Dr. Robert Brennan and Dr. Lilian Chooback for their advisement on this project. Also, I would like to thank the biology faculty and staff. I would like to thank the Seagraves lab members: Jailene Canales, Kayley Pate, Mckayla Muse, Grace Thetford, Kody Harvey, Jordan Guffey, and Kayle Patatanian for their hard work and support.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Olig1 and Sox10 Interact Synergistically to Drivemyelin Basic
    The Journal of Neuroscience, December 26, 2007 • 27(52):14375–14382 • 14375 Cellular/Molecular Olig1 and Sox10 Interact Synergistically to Drive Myelin Basic Protein Transcription in Oligodendrocytes Huiliang Li,1 Yan Lu,2 Hazel K. Smith,1 and William D. Richardson1 1Wolfson Institute for Biomedical Research and Department of Biology, University College London, London WC1E 6BT, United Kingdom, and 2Medical Research Council, Clinical Sciences Centre, Imperial College London, London W12 0NN, United Kingdom The oligodendrocyte lineage genes (Olig1/2), encoding basic helix-loop-helix transcription factors, were first identified in screens for master regulators of oligodendrocyte development. OLIG1 is important for differentiation of oligodendrocyte precursors into myelin- forming oligodendrocytes during development and is thought to play a crucial role in remyelination during multiple sclerosis. However, itisstillunclearhowOLIG1interactswithitstranscriptionalcofactorsandDNAtargets.OLIG1wasreportedlyrestrictedtomammals,but we demonstrate here that zebrafish and other teleosts also possess an OLIG1 homolog. In zebrafish, as in mammals, Olig1 is expressed in the oligodendrocyte lineage. Olig1 associates physically with another myelin-associated transcription factor, Sox10, and the Olig1/Sox10 complex activates mbp (myelin basic protein) transcription via conserved DNA sequence motifs in the mbp promoter region. In contrast, Olig2 does not bind to Sox10 in zebrafish, although both OLIG1 and OLIG2 bind SOX10 in mouse. Key words: Olig1; Olig2; Sox10; Mbp; oligodendrocyte; myelin; zebrafish; mouse; evolution; development Introduction directly regulates Mbp transcription (Stolt et al., 2002), and over- Myelin, the multilayered glial sheath around axons, is one of the expression of SOX10 alone is sufficient to induce myelin gene defining features of jawed vertebrates (gnathostomes). It is expression in embryonic chick spinal cord (Liu et al., 2007).
    [Show full text]
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]
  • SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure S1. RBPJ
    Xie et al. SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure S1. RBPJ correlates with BTIC marker expression. A-D. The TCGA GBM dataset was downloaded and correlations analyzed by R. RBPJ mRNA levels were highly correlated with (A) Olig2, (B) Sox2, (C) CD133, and (D) Sox4 levels. E. RBPJ is preferentially expressed in proneural glioblastomas. The glioblastoma TCGA dataset was interrogated for RBPJ mRNA expression segregated by transcriptional profile. The proneural tumors were further divided into G-CIMP (glioma CpG-island methylator phenotype) or non-G-CIMP. **, p < 0.01. ****, p < 0.0001. *****, p < 0.00001. Supplemental Figure S2. Targeting RBPJ induces BTIC apoptosis. A. 3691 BTICs were transduced with shCONT, shRBPJ-1, or shRBPJ-2. Lysates were prepared and immunoblotted with the indicated antibodies. shRNA-mediated knockdown of RBPJ was associated with increased cleaved (activated) PARP. B. 3691 BTICs were transduced with shCONT, shRBPJ-1, or shRBPJ-2. Apoptosis measured by Annexin V staining. Data are presented as mean ± SEM (two- way ANOVA; **, p < 0.01; n = 3). Supplemental Figure S3. Targeting RBPJ does not affect non-BTIC proliferation. Non-BTICs (Top, 3691; Bottom, 4121) were transduced with shCONT, shRBPJ-1, or shRBPJ-2. Cell proliferation was measured by CellTiter-Glo. 42 Xie et al. Supplemental Figure S4. RBPJ induces transcriptional profiles in BTICs distinct from Notch activation. A. In parallel experiments, 3691 BTICs were either treated with DAPT (at either 5 μM or 10 μM) vs. vehicle control (DMSO) or transduced with shRBPJ vs. shCONT. RNA-Seq was performed and the results displayed as a heat map with normalization to the relevant control.
    [Show full text]
  • Hormonal Regulation of Oligodendrogenesis I: Effects Across the Lifespan
    biomolecules Review Hormonal Regulation of Oligodendrogenesis I: Effects across the Lifespan Kimberly L. P. Long 1,*,†,‡ , Jocelyn M. Breton 1,‡,§ , Matthew K. Barraza 2 , Olga S. Perloff 3 and Daniela Kaufer 1,4,5 1 Helen Wills Neuroscience Institute, University of California, Berkeley, CA 94720, USA; [email protected] (J.M.B.); [email protected] (D.K.) 2 Department of Molecular and Cellular Biology, University of California, Berkeley, CA 94720, USA; [email protected] 3 Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143, USA; [email protected] 4 Department of Integrative Biology, University of California, Berkeley, CA 94720, USA 5 Canadian Institute for Advanced Research, Toronto, ON M5G 1M1, Canada * Correspondence: [email protected] † Current address: Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA 94143, USA. ‡ These authors contributed equally to this work. § Current address: Department of Psychiatry, Columbia University, New York, NY 10027, USA. Abstract: The brain’s capacity to respond to changing environments via hormonal signaling is critical to fine-tuned function. An emerging body of literature highlights a role for myelin plasticity as a prominent type of experience-dependent plasticity in the adult brain. Myelin plasticity is driven by oligodendrocytes (OLs) and their precursor cells (OPCs). OPC differentiation regulates the trajectory of myelin production throughout development, and importantly, OPCs maintain the ability to proliferate and generate new OLs throughout adulthood. The process of oligodendrogenesis, Citation: Long, K.L.P.; Breton, J.M.; the‘creation of new OLs, can be dramatically influenced during early development and in adulthood Barraza, M.K.; Perloff, O.S.; Kaufer, D.
    [Show full text]
  • Pharmacogene Regulatory Elements: from Discovery to Applications
    Smith et al. Genome Medicine 2012, 4:45 http://genomemedicine.com/content/4/5/45 REVIEW Pharmacogene regulatory elements: from discovery to applications Robin P Smith1,2†, Ernest T Lam2,3†, Svetlana Markova1, Sook Wah Yee1* and Nadav Ahituv1,2* Pharmacogenomics and gene regulatory elements: Abstract an emerging picture Regulatory elements play an important role in the Most pharmacogenomics studies to date have focused on variability of individual responses to drug treatment. coding variants of pharmacologically important proteins. This has been established through studies on three However, well-supported examples of variants in regu la- classes of elements that regulate RNA and protein tory elements of genes involved in drug response, such as abundance: promoters, enhancers and microRNAs. drug metabolizing enzymes and transporters (see review Each of these elements, and genetic variants within by Georgitsi et al. [1]), show that variants in noncoding them, are being characterized at an exponential pace regulatory sequences are also likely to be important by next-generation sequencing (NGS) technologies. In (Table 1). Th ree classes of regulatory elements have been this review, we outline examples of how each class of studied in this context: promoters, enhancers and element aff ects drug response via regulation of drug microRNAs (miRNAs). Each of these has a direct impact targets, transporters and enzymes. We also discuss on the abundance of messenger RNA (mRNA) (in the case the impact of NGS technologies such as chromatin of promoters and enhancers) and protein (in the case of immunoprecipitation sequencing (ChIP-Seq) and RNA miRNAs). Genetic variation within each of these elements sequencing (RNA-Seq), and the ramifi cations of new has been linked to human disease as well as interindividual techniques such as high-throughput chromosome diff erences in drug response.
    [Show full text]
  • Single Cell Regulatory Landscape of the Mouse Kidney Highlights Cellular Differentiation Programs and Disease Targets
    ARTICLE https://doi.org/10.1038/s41467-021-22266-1 OPEN Single cell regulatory landscape of the mouse kidney highlights cellular differentiation programs and disease targets Zhen Miao 1,2,3,8, Michael S. Balzer 1,2,8, Ziyuan Ma 1,2,8, Hongbo Liu1,2, Junnan Wu 1,2, Rojesh Shrestha 1,2, Tamas Aranyi1,2, Amy Kwan4, Ayano Kondo 4, Marco Pontoglio 5, Junhyong Kim6, ✉ Mingyao Li 7, Klaus H. Kaestner2,4 & Katalin Susztak 1,2,4 1234567890():,; Determining the epigenetic program that generates unique cell types in the kidney is critical for understanding cell-type heterogeneity during tissue homeostasis and injury response. Here, we profile open chromatin and gene expression in developing and adult mouse kidneys at single cell resolution. We show critical reliance of gene expression on distal regulatory elements (enhancers). We reveal key cell type-specific transcription factors and major gene- regulatory circuits for kidney cells. Dynamic chromatin and expression changes during nephron progenitor differentiation demonstrates that podocyte commitment occurs early and is associated with sustained Foxl1 expression. Renal tubule cells follow a more complex differentiation, where Hfn4a is associated with proximal and Tfap2b with distal fate. Mapping single nucleotide variants associated with human kidney disease implicates critical cell types, developmental stages, genes, and regulatory mechanisms. The single cell multi-omics atlas reveals key chromatin remodeling events and gene expression dynamics associated with kidney development. 1 Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. 2 Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
    [Show full text]